Recruiting

Testing a Mammography Decision Intervention in a Rural Setting

ClinicalTrials.gov IDNCT06522568

PhaseNA

Enrollment39

SponsorDartmouth-Hitchcock Medical Center

Age39 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Breast Cancer

About this study

The overall objective of this COBRE pilot project is to enhance the design of a 3-arm cluster randomized trial that will test the efficacy and mechanism of effect of the MyMammogram DA with or without a provider communication intervention. This will be accomplished through two aims: (1) Refine, with community partner input, a clinical trial protocol to optimize engagement among patients and primary care providers (PCPs) practicing in rural settings. In consultation with patients, PCPs, and informatics experts, the study team will refine site selection, randomization, patient and PCP recruitment, and data collection protocols to meet the needs of the rural health care delivery system and participants. The result of this aim will be a modified protocol and intervention strategy that is acceptable to partners. (2) Adapt and test trial and intervention implementation features to achieve protocol acceptance and adherence. The investigators will pilot the adapted three-arm randomized trial protocol in rural primary care settings that compares the MyMammogram DA with or without a risk summary provided to the PCP pre-visit, relative to usual care. Implementing the trial in two phases (n=15 each) will systematically identify barriers and facilitators to trial participation to refine protocols. Participants will receive acceptability surveys and investigators will conduct qualitative interviews with patients and PCPs to understand experiences with trial implementation from multiple perspectives.

Interventions

Behavioral: MyMammogram — An online breast cancer screening decision aid
Other: Provider communication — Provider will be provided with information from MyMammogram that includes patient's breast cancer risk and preferences for mammograms prior to the appointment

Primary outcomes

Intervention acceptability (within one day of completing the intervention)

Eligibility information

Patient Inclusion Criteria: * Females * Aged 39-49 * Upcoming appointment with a participating primary care provider (within 4 weeks) * English or Spanish-speaking Patient Exclusion Criteria: * Personal history of breast cancer (including lobular carcinoma in situ and ductal carcinoma in situ or atypical hyperplasia) * Mammogram in the prior 9 months Clinician inclusion: Any practicing primary care provider at a participating site.

Study locations

Cheshire Medical Center, Keene, New Hampshire 03431 United States
New London Hospital Primary Care, New London, New Hampshire 03257 United States
Newport Health Center, Newport, New Hampshire 03773 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.